The future of EU HTA
What will change in drug assessment as of 2025
The roadmap to a new process
In 2021, the adoption of the legislation for joint European Health Technology Assessment (EU HTA) initiated a new era for HTA. As of 2025, cancer and advanced therapy medicinal products will need to be assessed through a pan-EU lens.
While all stakeholders agree that pan-EU collaboration on HTA and harmonization of processes and requirements is valuable, the shift to a mandatory process leaves some open questions:
- What does HTA mean at the EU level?
- What are key concerns about the new process?
- How can you prepare for the future of EU HTA?
Download our latest whitepaper to help answer these questions and better prepare for the implementation of a pan-EU HTA.